Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving from 1.90% in May to 1.96%, indicating a collective rise in negative bets ...

Moderna's stock, down 91% from its peak, jumped 16% on positive Phase 2b results for its mRNA skin cancer vaccine, showing a 49% reduction in recurrence. This cancer vaccine is vital for Moderna to ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...